Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Infectious and Chronic Diseases?
4.2.2 Increasing Adoption of Automated Platforms
4.3 Market Restraints
4.3.1 Affordability for High-end Molecular Diagnostics
4.3.2 Limitations Associated with Reimbursement Scenario
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size in Value)
5.1 By Test
5.1.1 Lipid Panel
5.1.2 Liver Panel
5.1.3 Renal Panel
5.1.4 Complete Blood Count
5.1.5 Electrolyte Testing
5.1.6 Infectious Disease Testing
5.1.7 Other Tests
5.2 By Product
5.2.1 Instruments
5.2.2 Reagents
5.2.3 Other Products
5.3 By End User
5.3.1 Hospital Laboratory
5.3.2 Diagnostic Laboratory
5.3.3 Point-of-care Testing
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 BioMerieux
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Danaher Corporation
6.1.6 Siemens AG
6.1.7 Hologic Inc.
6.1.8 Qiagen NV
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Thermo Fisher Scientific
6.1.11 Quest Diagnostics Inc.
6.1.12 Sysmex Corporation
6.1.13 Sonic Healthcare Ltd
6.1.14 Charles River Laboratories


7 MARKET OPPORTUNITIES AND FUTURE TRENDS